Disclosures for "A Phase 1 Healthy Volunteer Dose Escalation to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Intravenous Human IgG1 Fc-F241A (NVG-2089) for the Treatment of CIDP "
-
Dr. Coffey has received personal compensation for serving as an employee of Nuvig Therapeutics.
-
Miss Oguno has received personal compensation for serving as an employee of Nuvig Therapeutics.
-
William Avery has stock in Nuvig Therapeutics.
-
Mrs. Coffey has received personal compensation for serving as an employee of Nuvig Therapeutics.
-
Ms. Mathew has nothing to disclose.
-
Mr. Leung has received personal compensation for serving as an employee of Nuvig Therapeutics.
-
Rev. Grimm has received personal compensation for serving as an employee of Nuvig Therapeutics. Rev. Grimm has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Nuvig Therapeutics.
-
Ms. Bright has received personal compensation for serving as an employee of Nuvig Therapeutics.
-
Dr. Ratnayake has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Nuvig Therapeutics.
-
Dr. Kim has nothing to disclose.
-
Dr. Conley has received personal compensation for serving as an employee of Nuvig therapeuics. Dr. Conley has stock in Nuvig Therapeutics.
-
Dr. Glicklich has received personal compensation for serving as an employee of Nuvig Therapeutics . Dr. Glicklich has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Nuvig Therapeutics . Dr. Glicklich has stock in Chinook Therapeutics.